Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACKR3 | P25106 | 3/20 | 0.37 |
| ▸ | AHCY | P23526 | 1/20 | 0.37 |
| ▸ | MMP9 | P14780 | 2/20 | 0.31 |
| ▸ | MMP1 | P03956 | 1/20 | 0.31 |
| ▸ | MMP3 | P08254 | 1/20 | 0.31 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.31 |
| ▸ | ADAM9 | Q13443 | 1/20 | 0.31 |
| ▸ | NAMPT | P43490 | 2/20 | 0.30 |
| ▸ | METAP2 | P50579 | 1/20 | 0.30 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1196800 | 0.91 | AHCY (0.35) | ACKR3AHCYMMP9MMP1MMP3 | |
| SCHEMBL1197274 | 0.89 | AHCY (0.35) | ACKR3AHCY | |
| SCHEMBL1197789 | 0.87 | ACKR3 (0.39) | ACKR3AHCYMMP9MMP1MMP3 | |
| SCHEMBL1027927 | 0.85 | AHCY (0.39) | ACKR3AHCY | |
| SCHEMBL1030102 | 0.84 | AHCY (0.47) | ACKR3AHCYNAMPT | |
| SCHEMBL1027823 | 0.84 | AHCY (0.45) | ACKR3AHCYNAMPT | |
| SCHEMBL1025183 | 0.84 | AHCY (0.39) | ACKR3AHCY | |
| SCHEMBL1197133 | 0.83 | AHCY (0.37) | ACKR3AHCY | |
| SCHEMBL1027114 | 0.83 | AHCY (0.37) | ACKR3AHCY | |
| SCHEMBL1027502 | 0.83 | AHCY (0.46) | ACKR3AHCYMMP9MMP1MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8513235-B2 | Homocysteine synthase inhibitor | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-08-20 | — | — | US | disclosed |
| US-20120196824-A1 | THERAPEUTIC AGENT FOR CEREBRAL INFARCTION | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-08-02 | — | — | US | disclosed |
| US-20110034440-A1 | HOMOCYSTEINE SYNTHASE INHIBITOR | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-02-10 | — | — | US | disclosed |
| EP-2275404-A1 | HOMOCYSTEINE SYNTHASE INHIBITOR | Mitsubishi Tanabe Pharma Corporation (JP) | 2011-01-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120196824-A1 | THERAPEUTIC AGENT FOR CEREBRAL INFARCTION | FABP7, TIMP3, MMP11 | ACKR3 1777/4885AHCY 4108/4885MMP9 104/4885 |
| US-20110034440-A1 | HOMOCYSTEINE SYNTHASE INHIBITOR | BHMT, CBS, BHMT2 | ACKR3 4604/4885AHCY 4/4885MMP9 1287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.